Two initial public offerings (IPOs) made it into the public markets last week, with insiders taking about two-thirds of the shares on offer. Next week’s action includes a cable TV operator, three REITs, and three blank-check companies.
Biotech firm Athenex Inc. (NASDAQ: ATNX) raised $66 million selling 6 million shares at $11, the low end of the expected price range. The shares got....More>>>
The stock market continued to gain ground on Monday, reflecting investor optimism about the potential for a favorable outcome in the planned U.S. meeting with North Korean leader Kim Jong Un in Singapore. Most major benchmarks gained modestly on the day, with the Nasdaq Compositerising and the Dow Jones Industrial Averagepicking up a few points. Some companies had particularly good news that sent....More>>>
Utility companies aren’t usually fan favorites among investors, but these protected and counter-cyclical companies are my favorites for a long-term portfolio. Consistent cash flow means high dividend yields and sales don’t fluctuate like in other industries.
—Recommended Link— This Tiny Biotech Is Set To Disrupt A $133 Billion Market
It’s like something....More>>>
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication.
Welcome to another edition of “3 Things In Biotech You Should Learn Today,” a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.
Amgen is going to hunt down the last remnants of ALL
On Dec. 15, 2017, the share of Omeros Corporation (NASDAQ:OMER) – a bioscience focusing on the innovation and commercialization of drugs to treat complement-mediated diseases, inflammation, and central nervous system disorders – appreciated $0.47 to trade at $19.68 for 3.52% profits (as of 2:47 pm ET). Since we featured the firm in the Integrated BioSci Interview with....More>>>
While its closest rivals Domino’s (NYSE:DPZ) and Papa John’s (NASDAQ:PZZA) have steadily delivered impressive growth in the United States Yum! Brands (NYSE:YUM) Pizza Hut has struggled.
Domino’s saw its same store domestic sales grow by 13% in its most recent quarter, the 22nd consecutive quarter of positive sales in its U.S. business.Papa John’s has not done quite....More>>>
Media coverage about Catabasis Pharmaceuticals (NASDAQ:CATB) has trended somewhat positive on Wednesday, according to Accern Sentiment. The research firm identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable.....More>>>
Puma Biotechnology (NASDAQ:PBYI)’s share price reached a new 52-week high and low on Thursday . The stock traded as low as $50.15 and last traded at $51.15, with a volume of 13342 shares trading hands. The stock had previously closed at $51.45.
PBYI has been the subject of several research analyst reports. Zacks Investment Research upgraded Puma Biotechnology from a “sell”....More>>>
Why do some companies’ shares trade at $100 or more each while others trade at substantially less? There are many factors that contribute to the price of a stock, the most important being the number of shares outstanding. After all, the share price multiplied by the number of shares available determines a company’s market cap, which is the true price at which the market values a company.
Not many companies have monopolies, though some get pretty close. That list includes Russian telecom giantMobile TeleSystems (NYSE:MBT), biotech playerGilead Sciences, Inc.(NASDAQ:GILD), and tobacco makerAltria Group, Inc. (NYSE:MO). Each one has a slightly different virtual monopoly and they clearly have vastly different businesses. But if you are looking for income from seriously entrenched industry....More>>>
What’s the riskiest big biotech stock on the market? According to market research firm EvaluatePharma, it’sCelgene (NASDAQ:CELG).
Many investors have been very bearish about Celgene for months. The company’s once-promising Crohn’s disease drug GED-0301 flopped miserably in a late-stage clinical study in October 2017. Celgene thoroughly embarrassed itself, with the....More>>>
Anika Therapeutics Inc (NASDAQ:ANIK) – First Analysis lowered their FY2019 earnings per share estimates for Anika Therapeutics in a research report issued on Tuesday, June 19th. First Analysis analyst now forecasts that the biotechnology company will post earnings per share of $1.34 for the year, down from their prior estimate of $1.52. First Analysis has a “Equal Weight”....More>>>
Media headlines about RXi Pharmaceuticals (NASDAQ:RXII) have trended somewhat positive on Tuesday, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. RXi....More>>>
Shares of Belgian biotech Galapagos (GLPG) have dipped considerably in the past couple months along with general weakness in the biotech sector, potentially offering would-be investors an entry point into the stock. Even after recent price action the stock has still increased by over 50% since my original recommendation in 2016 calling the firm 篓a long term buy in biotech篓.
Teachers Advisors LLC boosted its position in Concert Pharmaceuticals (NASDAQ:CNCE) by 293.9% during the fourth quarter, Holdings Channel reports. The fund owned 135,399 shares of the biotechnology company’s stock after purchasing an additional 101,026 shares during the quarter. Teachers Advisors LLC’s holdings in Concert Pharmaceuticals were worth $3,503,000 at the end of the most....More>>>